CPT 0227U: Comprehensive Urine Drug and Metabolite Screen from Aspenti Health

Headline: New PLA Code for Aspenti Health Urine Drug Screen Highlights Proprietary Test Coverage Questions

Lead: CPT code 0227U designates a Proprietary Laboratory Analyses (PLA) test — the Comprehensive Screen from Aspenti Health — used to detect drugs and metabolites in urine specimens to support identification of potential adverse drug interactions.

CPT code 0227U represents a manufacturer-specific laboratory assay that matters nationally as payers and providers navigate coverage and billing for proprietary tests. PLA codes are reportable when a single vendor or single laboratory offers a unique test, and they play an increasing role in outpatient toxicology, medication management, and population health programs focused on medication safety.

Key payers in scope for coverage considerations include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an explanation of the clinical purpose of the test, the expected service setting, and which payer policies are commonly relevant. The publication outlines benchmark topics such as payer coverage patterns, reimbursement and billing considerations tied to PLA coding, and clinical context for use in medication safety and toxicology screening.

This national summary provides operational clarity for billing, coding, and clinical teams about what CPT code 0227U denotes, why a PLA designation matters for payer interactions, and where to look for policy and reimbursement guidance. Data not available in the input.

Billing Code Overview

CPT code 0227U is a Proprietary Laboratory Analyses (PLA) code for the Comprehensive Screen from Aspenti Health. The test detects drugs and metabolites (break–down products) in a patient urine specimen to help identify potential adverse drug interactions.

Service Type: Laboratory drug and metabolite detection (urine)

Typical Site of Service: Clinical laboratory or outpatient phlebotomy/collection site

Clinical Context

A 42-year-old patient with chronic pain managed with multiple prescribed medications presents for routine monitoring and medication management. The clinician orders the Aspenti Health Comprehensive Urine Drug Screen (0227U) to detect prescribed drugs, illicit substances, and metabolites to assess adherence and identify potential drug–drug interactions that could cause adverse events. The specimen is a random urine sample collected during an outpatient clinic visit or at an affiliated laboratory. The lab performs the proprietary PLA test, reports detected analytes and metabolite patterns, and returns results to the ordering clinician who documents results in the patient record and uses them to inform medication reconciliation and risk mitigation decisions. Typical sites of service include outpatient clinics, physician offices, pain management clinics, behavioral health clinics, substance use disorder treatment centers, and hospital outpatient laboratories.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier (standard reporting)	Use when no special circumstances apply and full service is rendered.
`26`

Taxonomy Code	Specialty	Notes
207Q00000X	Pain Medicine	Clinicians managing chronic pain who order urine drug testing.
207L00000X	Psychiatry & Neurology	Behavioral health and addiction specialists ordering drug screens.
207RC0000X	Family Medicine	Primary care clinicians performing medication monitoring.
207P00000X	Internal Medicine	Internists overseeing complex medication regimens and monitoring adherence.
362X00000X	Clinical Laboratory	Clinical laboratory professionals responsible for performing the `0227U` PLA test.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`Z79.899`	Other long term (current) drug therapy	Commonly used for patients on chronic medications requiring ongoing drug monitoring.
`F11.20`	Opioid dependence, uncomplicated	Relevant for monitoring for illicit opioid use, adherence, and metabolites in urine drug testing.
`F11.10`	Opioid abuse, uncomplicated	Applicable when screening for misuse in patients with known substance use disorders.
`G89.2`	Chronic pain, not elsewhere classified	Indicates chronic pain patients who require medication monitoring to prevent interactions and misuse.
`Z91.19`	Patient's noncompliance with other medical treatment and regimen	Relevant when testing is used to assess adherence to prescribed therapy.
`F10.20`	Alcohol dependence, uncomplicated	May be included in substance use monitoring panels when polysubstance use is a concern.
`T50.995A`	Adverse effect of other narcotics and psychodysleptics, initial encounter	Relevant when drug testing is used to investigate suspected adverse drug interactions or toxicity.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81002`	Urinalysis, non-automated; without microscopy	Often performed alongside as a basic urinalysis to assess specimen integrity and urine characteristics prior to or with urine drug testing.
`80305`	Drug test, presumptive, any number of drug classes; any number of drug classes by screen method	May be used as an initial point-of-care or laboratory presumptive screen before or in conjunction with definitive PLA testing.
`80307`	Drug test, definitive (e.g., GC/MS, LC/MS/MS), qualitative or quantitative, multiple drug classes	Definitive confirmatory testing by mass spectrometry is commonly ordered following unexpected or presumptive positive results from the comprehensive PLA assay.
`36415`	Collection of venous blood by venipuncture	Not routinely required for urine testing but may be performed if blood toxicology or therapeutic drug monitoring is needed in the same clinical encounter.
`99000`	Handling and/or conveyance of specimen	Administrative or courier services related to transporting the urine specimen to the performing laboratory (use per payer policies).

OpenPayer

Summary & Overview